This prospective trial evaluated first-line osimertinib combined with platinum and etoposide in patients with EGFR-mutant lung adenocarcinoma harboring concurrent TP53 and RB1 alterations, who are at high risk for histological transformation. Despite incorporating SCLC-directed chemotherapy upfront, nearly half of the patients (5 of 11) experienced SCLC transformation, yielding a median progression-free survival of 11 months and a median overall survival of 33 months. Genomic and single-cell transcriptomic analyses revealed pronounced phenotypic plasticity towards SCLC, mesenchymal, and squamous lineages. These lineage shifts were driven by progressive disruption of the RB pathway and chromatin remodeling, which were further amplified under the selective pressure of osimertinib treatment.
This study introduces DNAmBERT, a Transformer-based deep learning model for non-invasive cancer diagnosis. It jointly models DNA sequence context and read-level methylation haplotype structure from cfDNA, addressing limitations of current computational methods. Evaluated across various platforms and cancer types, DNAmBERT achieved high performance with AUCs up to 0.99-1.00. The model supports multi-cancer and stage-aware classification, including early-stage disease, and demonstrates effective cross-cancer transfer learning.
This study investigated the transcriptomic profile and therapeutic opportunities in EGFR-mutant non-small cell lung adenocarcinoma (LUAD) that undergoes lineage transformation to small cell lung cancer (SCLC), a mechanism of acquired resistance to EGFR TKIs. By analyzing paired pre- and post-transformation samples from 32 patients, researchers characterized the immune microenvironment of transformed SCLC (T-SCLC). They found that T-SCLC exhibits an immunosuppressive microenvironment compared to EGFR-mutant LUAD, yet a more immunologically active one than primary SCLC. Patients with T-SCLC treated with first-line immunotherapy plus chemotherapy showed a median progression-free survival of 5.1 months and a median overall survival of 21.0 months. Immunotherapy exposure was associated with significantly longer overall survival, supporting the integration of immunotherapy in T-SCLC treatment.
This study developed a robust prognostic model for lung adenocarcinoma (LUAD) by focusing on PD-1-related genes. Utilizing advanced bioinformatics analyses and in vitro validations, a nine-gene risk model (ADA2, CD53, HLA-DMA, ITGAX, MYO1F, NCKAP1L, PTPRC, RENBP, TNFAIP8L2) was constructed. This model demonstrated strong predictive performance, stratifying patients into high- and low-risk groups with distinct prognoses. High-risk patients exhibited a worse prognosis and lower immune infiltration, while drug sensitivity analyses identified specific candidate therapeutic agents for each group.
This multicenter retrospective study analyzed 163 patients with transformed small-cell lung cancer (T-SCLC), a recognized resistance mechanism in EGFR-mutant lung adenocarcinoma. The study aimed to identify early predictors of histological transformation and evaluate post-transformation treatment outcomes. Researchers found a median transformation time of 25.8 months and a median post-transformation overall survival of 14.2 months in EGFR-mutant patients. A predictive model was developed, incorporating age, RB1/NTRK1 mutations, and secondary EGFR T790M mutation as independent risk factors. Taxane-based regimens emerged as a promising later-line therapeutic option for T-SCLC.
This study investigated the mechanisms and therapeutic targets of distant metastasis in lung adenocarcinoma (LUAD), with a focus on organotropism. By integrating digital spatial profiling (DSP), multiplex immunofluorescence (mIF), and clinical data, researchers developed highly accurate random forest models predicting organ-specific metastases to the brain, liver, adrenal gland, and bone. Key compartment-specific gene expression signatures were identified in tumor, immune, and stromal cells, including FKBP1A for brain and MOCOS for liver metastasis. The study also revealed distinct biological pathways and prognostic factors related to post-metastasis survival, providing promising new biomarkers and therapeutic targets.
This retrospective study evaluated the efficacy and prognostic factors of first-line bevacizumab plus chemotherapy in elderly patients (≥65 years) with advanced lung adenocarcinoma lacking driver gene alterations. Among 169 included patients, the bevacizumab-treated group demonstrated a median overall survival of 47 months and a median progression-free survival of 24 months. Multivariate analysis identified bevacizumab as an independent favorable prognostic factor for both progression-free and overall survival. Biomarkers related to inflammation, nutrition, and tumor burden were also associated with prognosis.
This study identifies ERO1A as a novel and promising biomarker for early-stage lung adenocarcinoma (esLUAD). High ERO1A expression is associated with poor prognosis, yet paradoxically, it correlates with an immune-activated tumor microenvironment. Tumors with elevated ERO1A levels demonstrate a superior response to immune checkpoint inhibitors. This biomarker could therefore aid in patient stratification and guide peri-operative therapeutic decisions.
This study investigates histologic transformation to lung squamous cell carcinoma (LUSC) in EGFR-mutant lung adenocarcinoma (LUAD) patients, an underrecognized resistance mechanism. Multiomic analyses revealed that patients with transforming or adenosquamous (LUAS) phenotypes experienced shorter overall survival on first-line osimertinib. Inactivation of the retinoblastoma (Rb) pathway, particularly via CDKN2A/B deletions, was identified as a key driver of this transformation. Furthermore, MET pathway upregulation was observed, and combined EGFR and MET inhibition demonstrated efficacy in preclinical models. These findings suggest novel strategies to counteract this aggressive form of resistance.
Zhonghua bing li xue za zhi = Chinese journal of pathology ·
This retrospective study investigated eight cases of multifocal micronodular pneumocyte hyperplasia (MMPH) associated with tuberous sclerosis complex (TSC), a rare benign pulmonary lesion. Patients typically presented with multiple ground-glass nodules in the lungs on CT scans and various clinical manifestations of TSC. A significant diagnostic challenge was highlighted, as intraoperative frozen sections were often misdiagnosed as early-stage lung adenocarcinoma. Next-generation sequencing revealed TSC1 or TSC2 gene mutations in most patients, confirming the association with TSC. All followed-up patients showed a favorable overall survival.
This prospective study evaluated gene expression profiling of seven genes (EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, TP53) in cell-free RNA (cfRNA) from exhaled breath condensate (EBC) in patients with advanced lung adenocarcinoma. Results indicated that PIK3CA showed the best diagnostic performance in distinguishing patients from healthy controls. High expression of FGFR2 and PIK3CA was associated with significantly shorter overall survival, highlighting their prognostic relevance. EGFR expression demonstrated a strong correlation between EBC and plasma, and low EGFR expression was linked to longer survival in patients receiving chemotherapy alone. This non-invasive EBC-based approach offers potential for molecular characterization and patient stratification.
This retrospective study analyzed 120 cases of lung adenocarcinoma (LUAD) with malignant serous effusions (MSE) to characterize their clinicopathologic, molecular, and prognostic features. Pleural effusions were most common, but pericardial involvement was associated with the shortest overall survival. Molecular profiling revealed TP53 mutations and actionable alterations in genes such as EGFR, KRAS, BRAF, ALK, and ROS1. NKX2-1 (TTF-1) negativity and the absence of actionable alterations were independent adverse prognostic factors, with dual NKX2-1/CD274 (PD-L1) negativity defining the poorest prognosis subgroup. Immunotherapy-based regimens and tyrosine kinase inhibitors showed varying survival benefits.
This study characterized the molecular architecture of the tumor microenvironment (TME) in lung adenocarcinoma (LUAD) with somatic BRCA1/2 mutations, using single-cell sequencing and multi-omics data. BRCA1/2 mutations are linked to increased genomic instability and poor prognosis, yet predict better clinical outcomes with immune checkpoint blockade (ICB) treatment. BRCA1 mutations correlate with an upregulated type I IFN/IFN-γ signature and CD8+ T cell activation, while BRCA2 mutations are associated with inflammatory responses and enhanced MHC-II antigen presentation, influencing CD4+ T cell differentiation. The study also identified tissue-resident memory T cell (Trm) subsets as predictors of ICB response and found that a cancer-promoting program activated by BRCA1 is vulnerable to histone deacetylase inhibitors.